NCT07326709ClinicalTrials.gov
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
בקצרה
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…
שלב 3דרושים 770 משתתפים117 אתרים27 מדינות
קטגוריות
רשום במרשם אחד
- ClinicalTrials.govNCT07326709פתיחת רשומה זו ב־ClinicalTrials.govסונכרן לפני חודשיים
מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.
מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.
מתעניינים במחקר הזה?
התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 41 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.
How this score is built
- Enrolment28/40
770 participants (target)
- Site count19/25
41 sites
- Country count12/15
9 countries
- Planned duration9/10
Planned over about 50 months
- Sponsor scale10/10
Novartis Pharmaceuticals has led 1,104 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
תקציר
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
מצבים רפואיים
- Huntington Disease
זכאות
| מין | הכול |
|---|---|
| גילאים | 21 Years – 70 Years |
| מתנדבים בריאים | לא |
זכאות כפי שנכתבה במרשם
זכאות במשפטים פשוטים
הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.
תכנון המחקר
| סוג המחקר | התערבותי |
|---|---|
| שלב | שלב 3 |
| הקצאה | אקראי |
| מודל ההתערבות | PARALLEL |
| מטרה ראשית | TREATMENT |
| הסתרה | QUADRUPLE (4) |
| גיוס | דרושים 770 משתתפים |
נותן חסות ושותפים
- Novartis Pharmaceuticals נותן חסות
זרועות והתערבויות
- VotoplamEXPERIMENTAL
Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
- PlaceboPLACEBO_COMPARATOR
Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
התערבויות
- תרופה Placebo
Placebo
- תרופה Votoplam (blinded)
Votoplam (blinded) active treatment
מדדי תוצאה
מדד תוצאה ראשוני
Change from Baseline in cUHDRS score
The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.
מסגרת זמן Baseline, Month 36
מדד תוצאה משני
Change from Baseline in UHDRS-TFC
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.
מסגרת זמן Baseline, Month 36
מדד תוצאה משני
Change from Baseline in UHDRS-IS
The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
מסגרת זמן Baseline, Month 36
מדד תוצאה משני
The time to decline in TFC score by at least one or IS score by at least 10
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
מסגרת זמן Baseline to end of treatment up to 36 months
מדד תוצאה משני
Change from Baseline in UHDRS-TMS
The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.
מסגרת זמן Baseline, Month 36
מדד תוצאה משני
Change from Baseline in SDMT
The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.
מסגרת זמן Baseline, Month 36
מדד תוצאה משני
Change from Baseline in SWRT
The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.
מסגרת זמן Baseline, Month 36
מדד תוצאה משני
Percent change from Baseline in blood mHTT protein
The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.
מסגרת זמן Baseline to steady state and up to 36 months in blood mHTT protein
מדד תוצאה משני
Change from Baseline in serum NfL
Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.
מסגרת זמן Baseline, Month 36
מדד תוצאה משני
Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal
Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.
מסגרת זמן Baseline to up to 36 months
תאריכים
| תאריך התחלה | 24 במרץ 2026 (בפועל) |
|---|---|
| סיום ראשוני | 2 באפריל 2030 (משוער) |
| סיום | 30 באפריל 2030 (משוער) |
| פורסם לראשונה | 8 בינואר 2026 (בפועל) |
| עודכן לאחרונה | 22 בספטמבר 2026 |
| התוצאות פורסמו | לא צוין ברשומת המרשם |
| המצב אומת לאחרונה | ספטמבר 2026 |
בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.
מיקומים
117 אתרים מגייסים
Argentina
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Buenos Aires | מגייס | |
| Instituto Argentino de Investigación Neurológica (IADIN) | CABA | Buenos Aires | מגייס |
| Centro de Investigaciones Metabólicas (CINME) | CABA | Buenos Aires | מגייס |
| Novartis Investigative Site | Ciudad de | Buenos Aires | מגייס |
Australia
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Caulfield South | Victoria | מגייס |
| Novartis Investigative Site | Westmead | New South Wales | מגייס |
Belgium
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Leuven | Vlaams Brabant | מגייס |
Bulgaria
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Sofia | מגייס | |
| Novartis Investigative Site | Sofia | מגייס |
Canada
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| CUSM Montreal Neurological Institute | Montreal | Quebec | מגייס |
| Centre de recherche du CHUM | Montreal | Quebec | מגייס |
| North York General Hospital | North York | Ontario | מגייס |
China
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Beijing | מגייס | |
| Novartis Investigative Site | Beijing | מגייס | |
| The Second Xiangya Hospital of Central South University | Changsha | Hunan | מגייס |
| West China Hospital of Sichuan Uni | Chengdu | Sichuan | מגייס |
| Novartis Investigative Site | Fuzhou | Fujian | מגייס |
| Novartis Investigative Site | Guangzhou | Guangdong | מגייס |
| Novartis Investigative Site | Guangzhou | Guangdong | מגייס |
| The Second Affiliated Hosp Of Zhejiang Univ School Of Medicine | Hangzhou | Zhejiang | מגייס |
| Novartis Investigative Site | Shanghai | מגייס | |
| Tongji Hos Affiliated Tongji Medical College of Huazhong | Wuhan | Hubei | מגייס |
Colombia
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Medellín | מגייס |
Czechia
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Brno | מגייס | |
| Novartis Investigative Site | Prague | מגייס |
Denmark
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Copenhagen | מגייס |
France
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Angers | France | מגייס |
| Novartis Investigative Site | Marseille | מגייס | |
| Novartis Investigative Site | Montpellier | מגייס |
Germany
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Aachen | מגייס | |
| Novartis Investigative Site | Bochum | מגייס | |
| Novartis Investigative Site | Münster | מגייס | |
| Novartis Investigative Site | Tübingen | מגייס | |
| Novartis Investigative Site | Ulm | מגייס |
Hungary
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Budapest | מגייס | |
| Novartis Investigative Site | Szeged | מגייס |
Israel
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Tel Aviv Sourasky Med Ctr Ichilov | Tel Aviv | מגייס |
Italy
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Bologna | BO | מגייס |
| Novartis Investigative Site | Brescia | BS | מגייס |
| Novartis Investigative Site | Milan | MI | מגייס |
| Novartis Investigative Site | Milan | MI | מגייס |
Japan
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Bunkyo Ku | Tokyo | מגייס |
| Novartis Investigative Site | Kashihara | Nara | מגייס |
| Novartis Investigative Site | Sagamihara | Kanagawa | מגייס |
Netherlands
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Leiden | South Holland | מגייס |
| Novartis Investigative Site | Maastricht | Limburg | מגייס |
Poland
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Krakow | POL | מגייס |
Portugal
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Lisbon | מגייס | |
| Novartis Investigative Site | Porto | מגייס |
Romania
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Novartis Investigative Site | Bucharest | מגייס |
67 אתרים נוספים מצוינים ברשומת המרשם.
מסמכי המחקר
לא צורפו מסמכים ברשומת מרשם זו.
שינויים לאורך זמן
- 22 בספטמבר 2026
אתר נוסף
35 sites added (117 total)
82117
- 31 באוגוסט 2026
אתר נוסף
22 sites added (82 total)
6082
- 11 באוגוסט 2026
אתר נוסף
9 sites added (60 total)
5160
- 29 ביולי 2026
אתר נוסף
10 sites added (51 total)
4151